LPCN 8-K: SEC filing
Lipocine Inc.
Filed with the SEC on · accession 0001493152-26-050842
LPCN filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Lipocine Inc. announced that the first participant has been dosed in its BLOOM Phase 3 clinical study of LPCN 1154 for the treatment of postpartum depression.
Key details
✦ Ask GOAX AI about this filing — what it means for LPCN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for LPCN?
Click hereFrequently asked questions
What did LPCN file with the SEC on Nov 10, 2026?
LPCN filed a 8-K (SEC filing). Lipocine Inc. announced that the first participant has been dosed in its BLOOM Phase 3 clinical study of LPCN 1154 for the treatment of postpartum depression.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other LPCN SEC filings
Get alerts when LPCN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days